Continuing Pneumococcal Vaccination After Gavi Transition in Kenya at Full Price is Cost-effective and Could Save Thousands of Lives

Kanopi

This news release was originally published on EurekAlert. Below is an excerpt from the news release.

Co-led by the London School of Hygiene & Tropical Medicine and the KEMRI-Wellcome Trust Research Program, the Pneumococcal Conjugate Vaccine Impact Study estimated that continuing the vaccine beyond 2022 would prevent – in the first ten years – more than 100,000 children and adults from contracting pneumococcal disease and save the lives of 14,000 children and adults who would otherwise have died.

The cost per year of healthy life saved (US $153) was considerably less than Kenya’s annual gross domestic product (GDP) per person (US $1,790 in 2018), which meets – and far exceeds – the World Health Organization (WHO) GDP-related threshold for ‘very cost-effective’ health interventions.

The researchers say this study offers important evidence for policymakers at what is a crucial time for countries that have to decide whether to continue vaccine programs that have benefited from Gavi’s subsidy of the cost of vaccines once their economies grow and Gavi support diminishes.

You May Also Like

What is the cost of delivering vaccines through integrated campaigns? Evidence from Nigeria and Sierra Leone

Findings from bottom-up costing studies of integrated vaccination campaigns in Nigeria and Sierra Leone has been published in BMC Health Services Research. The research, conducted by ThinkWell and the University of Nigeria, Nsukka, estimated the costs of a campaign held in 2019 in Sierra Leone with measles-rubella vaccine and oral polio vaccine, during which nutrition … Read More

Immunization Delivery Cost Catalogue update: The state of the evidence on the cost of delivering immunisation in low- and middle-income countries

ThinkWell is pleased to present an updated version of the Immunization Delivery Cost Catalogue, or IDCC, the most comprehensive, current, and standardized database on the cost of delivering vaccines in low- and middle-income countries. Based on a systematic review of over 22,000 publications, the updated IDCC presents 1,156 unique unit costs from 119 publications, in … Read More

Delivering 270M+ COVID-19 vaccines at just $0.29 per dose: The Bangladesh experience

Bangladesh launched its COVID-19 vaccination program in February 2021 with the ambitious aim of reaching 80% of the population with two doses. The program used a phased approach, initially targeting priority groups, and expanding eligibility over time as supply ramped up. By June 2022, the country had achieved its goal—having delivered over 270 million COVID-19 … Read More